

PRESS RELEASE – FOR IMMEDIATE RELEASE–

IntegraGen – Continued growth of the genomic services, first sales of autism risk assessment in the USA

EVRY, 11TH OF FEBRUARY 2013 - IntegraGen (FR0010908723 - ALINT), a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, announces today its sales for the year ending December 31st, 2012.

<i>In K€</i>	2012	2011	Var (%)	H2 2012	H2 2011	Var (%)
Turnover	4,748	4,650	+2.1%	2,492	2,152	+15.8%

Continued growth of Genomic Services sales

After an outstanding 2011 which showed a 45% growth in sales of genomic services, IntegraGen has continued its development with revenues of 4.75 M€, up 2.1% and bookings up 15%, compared to 2011.

Revenue growth accelerated during the second half of the year with revenues of 2,492 k€, representing growth of 10% over the first half of the year and 16% growth compared with S2 2011.

Sequencing activities made the largest contribution to this growth, again demonstrating the leadership of IntegraGen’s scientific, technical and sales team in providing genomic services to academic and corporate research teams.

First sales of Autism tests in the USA

IntegraGen launched the ARISK[®] Test, a risk assessment test for autism for siblings of an affected proband, during the summer of 2012. Initial physician orders have demonstrated the validity of IntegraGen’s organization centered around its contracted CLIA laboratory and expanded its interaction with the clinicians dealing with autism, a condition that affects one child in 88*. These first sales have enabled IntegraGen to initiate a collaborative dynamic with pediatricians, child psychiatrists and child neurologists.

Bernard Courtieu, CEO of IntegraGen stated: *"2012 has been the year of notable change in our development with two major challenges to deal with. We maintained our growth in spite of an outstanding previous year while also confirming our leadership and ability to continue our development in the area of Genomic Services. 2012 was also the year of the launch of the first of its kind autism genetic risk assessment based on our internal R&D efforts. Our first test sales demonstrate that physicians agree that the ARISK[®] Test provides clinical utility by allowing children at risk of autism to be referred very early to specialized diagnostic centers in order to benefit from early intervention. We are extremely pleased that we achieved these milestones in 2012 and look forward to continue to grow in 2013."*

Next release: annual results will be published on April 15th, 2013, before market

INTEGRAGEN

IntegraGen is listed on Alternext of the NYSE Euronext in Paris (Isin: FR0010908723 – Mnémo: ALINT)

Founded in 2000, IntegraGen is a biotechnology company specialized in the research and identification of genetic biomarkers for the development and marketing of products and services for molecular diagnosis. The IntegraGen mission is to offer clinicians new personalized tools for diagnosis, treatment and therapy. IntegraGen and its American affiliate IntegraGen Inc. strive for the prevention and proactive management of complex, debilitating illnesses by delivering the best response to the needs of patients, clinicians and associations. The Business Genomic Services division at IntegraGen also provides cutting edge services in the genotyping domain for scientific research. With research and intellectual property aimed essentially at autism and oncology, IntegraGen's strategy is to offer a range of products and services for molecular diagnosis incorporating strong added value, favoring personalized medicine for complex illnesses.

As of December 31, 2012, IntegraGen has 31 employees. The Company had annual revenues of €4.6M from services for the fiscal year 2011. Its headquarters are located at Genopole d'Evry. The Company is also present in the United States through its affiliate, IntegraGen Inc., based in Cambridge, MA.

IntegraGen is listed on Alternext of the NYSE Euronext in Paris (Isin: FR0010908723 – Mnémo: ALINT)
More information is available in the website: www.integragen.com

CONTACTS



INTEGRAGEN

Bernard Courtieu
CEO
Tel: +33 (0)1 60 91 09 00

Laurence Riot-Lamotte
CFO
contact@integragen.com
Tel: +33 (0)1 60 91 09 09

NEWCAP.

Investors and Media relationship
Axelle Vuillermet / Louis-Victor Delouvrier /
Nicolas Merigeau
integragen@newcap.fr
Tel: +33 (0)1 44 71 94 94

** source: Centers for Disease Control and Prevention –www.cdc.gov/features/countingautism*